Tyme
CompanyUnited StatesFounded 1975
Tyme develops one asset, in phase 2 (SM-88 in pancreatic cancer). Mostly small molecule acting on Oxidative stress and ROS signalling and mTOR signalling; based in the United States, founded in 1975.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Metabolic-altering therapy component using modified dysfunctional tyrosine alongside MPS to disrupt cancer metabolism.
Phase 2, Small molecule, Oxidative stress and ROS signalling, mTOR signalling, pancreatic cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials2
- Similar companies6